Kornimate/medical-research-clean huggingface dataset:
oral self care protocol and oral mucositis

Conditions: Mucositis Oral

Summary: objective: this study was conducted in order to examine the effect of oral self-care protocol based on orem's self-care deficiency theory on oral mucositis and self-care agency. method: this study was conducted as a randomized controlled trial between august 2021 and july 2022, patients with hematological malignancies receiving high-dose chemotherapy at the izmir ege university faculty of medicine hospital and izmir training and research hospital. the sample of the study consisted of a total of 60 patients, including 30 application groups and 30 control groups, who met the inclusion criteria using the computer-based stratified randomization method. the study data were collected using "patient information questionnaire," "who-oral mucositis toxicity scale," "oral assessment guide," "self-care agency scale," "data collection form prepared according to orem's self-care deficiency nursing theory," "oral care chart," and "oral cavity photography." the oral self-care protocol, which includes training and oral care practices, was applied to the application group for 21 days from the beginning of chemotherapy treatment. the control group was not subjected to any oral care attempts by the researcher and received standard nursing care in the clinic. the data were evaluated by descriptive statistics, the chi-square test, the mann-whitney u test, the mc ne-mar test, the kappa compliance test, and the t test in dependent and independent groups. keywords: chemotherapy; hematological malignancy; oral mucositis; oral self-care protocol; orem's theory; self-care agency; nursing


Eligibility criteria:
inclusion criteria: * willing to participate, * have the ability to read and write, * volunteer for oral cavity photography, * possess a platelet value above 20,000/mm3, and * have intact oral mucous membrane integrity. exclusion criteria: * who received combined radiotherapy and chemotherapy treatments * had incomplete questionnaire responses.

Keywords: oral mucositis oral self care protocol orem's nursing theory self-care agency
treating unhelpful suspicious thoughts in adolescents (trust): a school-based case series

Conditions: Paranoia

Summary: the goal of this acceptability and feasibility trial is to identify whether a six-session intervention for suspicious thoughts is feasible and acceptable to school-based adolescents. the main research question is: is it feasible and acceptable to offer a brief imagery and values-based intervention for adolescents experiencing paranoia in schools? aims the primary aim of the current study is to identify whether a six-session brief intervention delivered in schools is feasible and acceptable to young people experiencing paranoia. secondarily, it aims to identify preliminary outcomes of such an intervention on levels of paranoia, as measured by the revised green et al., paranoid thoughts scale (r-gpts). participants will be screened for paranoid thoughts and those eligible will be offered a six-session intervention. participants will be asked to complete various measures prior to and following therapy.


Eligibility criteria:
inclusion criteria: * age 16+ * attending participating school * low risk * no current mental health support * symptoms of paranoia i.e. scoring above 11 on r-gpts part b subscales, equating to "moderately severe" paranoia and above exclusion criteria: * evidence of a primary alcohol or substance dependence issue at initial assessment; * developmental disability; * not fluent in english (due to questionnaire validity issues); * receiving another therapy at the same time; * moderate to high levels of risk

Keywords: paranoia adolescents school feasibility acceptability
the effect of cognitive functional therapy on patients with non-specific chronic low back pain

Conditions: Chronic Low Back Pain

Summary: the purpose of this study is to evaluate whether individual cognitive functional therapy (cft), when compared to group exercise classes is effective in reducing pain and disability in patients with non-specific chronic low back pain.

a multi-centre randomised study with 6 month, 12 month and 36 month follow up will be used. patient with non- specific chronic low back pain will be assessed for eligibility. the patients fitting the inclusion criteria will be randomised to receive either the individual cft or the group classes consisting of education and exercise. participants' pain, disability, socio-economic status, beliefs, fear, catastrophizing, self-efficacy, general health, stress levels, as well as number and cost of treatments will be evaluated using a range of outcome measures at the start and on completion of the treatment. patients will receive another copy of the questionnaires in the post at 6 month, 12 months and 36 months after treatment to reassess clinical outcomes. if a participant does not respond to follow-up, they will be telephoned to ask if they wish to complete the questionnaires.

Eligibility criteria:
inclusion criteria: * aged between 18 and 75 * chronic low back pain greater than 6 months duration * score greater than 14% for disability on oswestry disability index (odi) * independently mobile (with or without aids), to be capable of participating in a rehabilitation programme exclusion criteria: * primary pain area is not the lumbar spine (from t12-buttocks) * leg pain as the primary problem (nerve root compression or disc prolapse with true radicular pain/radiculopathy, lateral recess/central or spinal stenosis with primary leg pain) * \<6 months post lumbar spine or lower limb or abdominal surgery * pain relieving procedures such as injection based therapy (e.g epidurals) and day case procedures (e.g rhizotomy) in the last 3 months * pregnancy * rheumatologic/inflammatory disease (e.g. rheumatoid arthritis (ra), ankylosing spondylitis (as), psoriatic arthritis, lupus, scheuermann's disease) * progressive neurological disease (e.g. multiple sclerosis (ms), parkinson's disease (pd), motor neuron disease (mnd) * unstable cardiac conditions * red flag disorders like malignancy/cancer, acute traumas like fracture (\<6 months ago) or infection, spinal cord compression/cauda equina

Keywords: non-specific chronic low back pain cognitive functional therapy exercise classes
eu safety and efficacy study regarding the r3 acetabular hip system

Conditions: Degenerative Joint Disease

Summary: the objective of this study is to determine the long-term safety and effectiveness from the r3 acetabular hip system. the study hypothesis is that implant survivorship of the r3 cup is at least 97% at 3 years, 95% at 5 years, 93% at 7 years, and 90% at 10 years follow-up.

this is a multicenter prospective observational post-market clinical follow-up study that will include 500 patients who will have total hip replacement with the r3 acetabular system and either cemented or cementless hip stem. effectiveness will be assessed by comparison of changes in parameters contained in the hoos questionnaire and based upon incidence of revision and change in harris hip score and ucla rating. safety will be measured by assessing all adverse events experienced by patients from study enrolment through to study completion.

Eligibility criteria:
inclusion criteria: subjects must meet all of the following characteristics for inclusion in the study. * patient is 18-75 years old and he/she is skeletally mature * patient requires primary total hip arthroplasty due to non-inflammatory degenerative joint disease (e.g. osteoarthritis, post-traumatic arthritis, avascular necrosis, dysplasia/ddh or inflammatory joint disease (e.g., rheumatoid arthritis) * patient has met an acceptable preoperative medical clearance and is free from or treated for cardiac, pulmonary, hematological, etc., conditions that would pose excessive operative risk * the patient is willing to comply the follow-up schedule exclusion criteria: subjects with any of the following characteristics must be excluded from the participation in the study. * patient has active infection or sepsis (treated or untreated) * patient is a prisoner or has an emotional or neurological condition that would pre-empt their ability or unwillingness to participate in the study including mental illness, mental retardation, linguistic insufficiencies (i.e. immigrants), or drug/alcohol abuse. * patients with acute hip trauma (femoral neck fracture)

Keywords: degenerative joint disease total hip arthroplasty
efficacy of information system regarding the consumption of antibiotics and bacterial resistance in primary care

Conditions: Chronic Disease

Summary: france is a country strong consumer of antibiotics in europe, specially in primary care. outpatient antibiotic use represents around 90% of total antibiotic use and prescriptions come mainly from general practitioners. a literature review of antibiotic stewardship in primary care show that there is no evaluation of interest of giving information about consumption of antibiotics and bacterial resistance to general practitioners. the objective of this study is to demonstrate that practitioners implicated in the followed of consumption of antibiotics and bacterial resistance around their geographical area of practice could change and improve their practices in good use of antibiotics.


Eligibility criteria:
inclusion criteria: * general practitioners in a "meurthe-et-moselle" french department exclusion criteria: * general practitioners out of "meurthe-et-moselle" french department

Keywords: antibiotics primary care stewardship general practitioners
north west london pebble pathway: automated osa diagnosis

Conditions: Obstructive Sleep Apnea; Sleep Apnea

Summary: patients with obstructive sleep apnoea (osa) wait up to two years for a diagnostic test. early diagnosis enables optimal treatment, mitigating risks including heart failure, lung disease, and stroke. current diagnostic approaches are expensive (£391), time-consuming (\>1-hour interpretation), uncomfortable (cables/tubes/wires), and inequitable (multiple hospital visits). overcoming all these limitations, we have designed and will investigate a straigh-to-test automated diagnostic pathway for osa. this will use the acupebble, a miniature wearable acoustic sensor and the first regulated technology for automated, at-home diagnosis. the test is cheap (\< £100); time-saving; endorsed by patients, and accessible (posted directly to patients). this project will measure the impact of a potentially transformative, innovative, and scalable diagnostic pathway using acupebble technology.

the investigators are conducting a prospective implementation and health economic study of a novel straight-to-test (stt) clinical diagnostic pathway for osa, using a novel, regulatory-approved wearable medical device for automated diagnosis of osa in the home setting (acupebble sa100). the setting is real-world direct clinical care, with participation from three nhs sleep medicine centres servicing the north west london region. inclusion criteria is primary care referrals for osa investigation were triaged onto the pathway based on predetermined criteria, compared to a historical cohort of patients undergoing stt using cardiorespiratory polygraphy (cr-pg) technology serving as a control group. the primary outcome is time-to-diagnosis. secondary outcomes include nhs cost-saving per patient; surrogates for health equity (e.g. test completion rates, time/cost of journeys saved); and carbon footprint reduction from averted patient journeys (sustainability).

Eligibility criteria:
inclusion criteria: * osa testing referral from primary care exclusion criteria: * unable to follow test instructions
iti-007 (lumateperone tosylate) for schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to offer open label iti-007 treatment to patients who poorly respond or poorly tolerate approved medications.

patients will be started on iti-007 and current medication will be slowly discontinued within the first 7 days of starting iti-007, with some flexibility allowed if clinically indicated. no patients will be left unmedicated because of this study. patients will be seen weekly for the first 4 weeks, biweekly for the second month and then monthly for six months. patients will be monitored by clinical and safety rating scales, and will be required to show improvement after 3 months to remain in this study. patients not improving at this time will be assessed for the risks/benefits of continuing.

Eligibility criteria:
inclusion criteria: * diagnostic and statistical manual of mental disorders, 5th edition (dsm-5) diagnosis of schizophrenia or schizoaffective disorder * has capacity to provide informed consent * medically stable for study participation * judged clinically not to be at significant suicide or violence risk * inadequate response or tolerability to previously antipsychotic therapy, as defined by at least one of the following: prior clozapine failure, a panss\>80 despite at least six weeks of a current antipsychotic therapy, a clinical global impressions scale-improvement (cgi-i) of 4 after at least two six week trials of antipsychotics (retrospective assessment) or failure to tolerate an adequate dose of at least antipsychotics (as defined by the physicians desk reference) exclusion criteria: * substance abuse within last 90 days * ecg abnormality that is clinically significant * pregnancy, lactation, or lack of use of effective birth control * presence or positive history of significant unstable medical or neurological illness (including any history of seizure disorder, hepatitis, renal insufficiency or mental retardation), history of hiv * clinically significant abnormal laboratory tests, positive for hepatitis b or c or liver function tests (lfts) \> 2x upper limit of normal, use of strong cyp3a4 inhibitors or inducers * history or presence of concomitant major psychiatric illness. * use of other antipsychotic medications at baseline. * use of another investigational medication in the previous 4 weeks
opioid rapid response system: naloxone training in communities

Conditions: Opioid Overdose

Summary: the pervasive impact of the opioid epidemic has touched all layers of society for the past two decades, resulting in over 115 deaths daily and imposing annual costs of $78.5 billion. responding swiftly to overdoses, akin to various medical emergencies, poses a significant challenge, particularly in geographically dispersed rural areas and densely populated urban settings. effectively delivering the life-saving drug naloxone, which counteracts the effects of overdoses, necessitates a well-coordinated and cost-efficient response system. simply opting for widespread distribution of naloxone, even with citizen involvement, proves to be a financially burdensome approach when compared to more targeted strategies. moreover, obstacles such as limited access, inadequate or unavailable naloxone training, and delayed response times from emergency responders compound the problem. addressing these issues, the proposed opioid rapid response system (orrs) project seeks to advance prevention science by adopting an innovative approach that incorporates technology and contemporary communication theory. the primary objective of the orrs project is to mitigate opioid overdose deaths by enlisting and training citizens to administer naloxone in response to such events. leveraging the pulsepoint health app, which connects citizens to cardiac events, the orrs project will extend its capabilities to respond to overdose incidents. this initiative involves comprehensive development of orrs, followed by a randomized clinical trial on a national scale to assess its effectiveness. the study aims to contribute to both prevention and implementation science by identifying optimal recruitment strategies and testing a model of online training. in pursuit of these objectives, the study is guided by the following specific aims: sa 1: refine and complete the development of orrs. sa 2: conduct a randomized clinical trial to evaluate the effectiveness of the intervention. sa 3: prepare orrs for dissemination.


Eligibility criteria:
inclusion criteria: * citizens who live in participating pulsepoint communities * must to be 18 and older * must be fluent in english * must have access to the mobile data and able to download and use apps in a smartphone exclusion criteria: * citizens who do not live in participating pulsepoint communities * under 18-year-old * citizens who are not fluent in english * citizens who do not have access to mobile data and unable to download and use apps in a smartphone.

Keywords: naloxone training community-engagement
a cross-sectional study of ocular manifestations during the covid-19 pandemic in hubei province

Conditions: COVID-19; Ocular Surface Disease

Summary: to investigate the clinical features of ocular manifestations during the novel coronavirus pneumonia pandemic in hubei at the end of 2022

during late 2022 covid-19 pandemic ocular discomforts were common in people with mild systemic symptoms, but most resolve on their own without any treatment. the disease spectrum of ophthalmology outpatient clinics is affected by the covid-19 pandemic. in our study, we observed that the incidence of keratitis and acute angle-closure glaucoma in phase a was significantly higher than that in phase b and c.

Eligibility criteria:
inclusion criteria: * 1. 2022.12.7 to 2023.2.6 people surveyed by wechat questionnaire star 2. 2021.12.7 to 2022.1.6 and 2022.11.7 to 2023.1.6 patients who received ophthalmology treatment in zhongnan hospital of wuhan university and qichun people's hospital exclusion criteria: * 1. currently hospitalized patients. 2. severe patients. 3. incomplete information. 4. cannot be contacted by telephone. 5. refuse questionnaire survey. 6.the electronic medical record information is incomplete. 7. those who do not go to the ophthalmic clinic after registration. 8.severe patients. 9. cannot be contacted by phone.
integrating well-woman and well-baby care to improve parenting and family wellness

Conditions: Primary Care

Summary: we hypothesize that relative to families who receive standard individual postpartum and pediatric care, families that receive group care will be more likely to have: * improved maternal and child health behaviors: i.e increased breastfeeding, exercise, child safety measures in the home and decreased smoking. * better health care use for babies: i.e. attend more care visits, on-time and complete immunizations and decreased emergency services use. * better psychosocial outcomes for the families: i.e. decreased stress and depression, and increased social support. * improved parenting skills: i.e. improved knowledge of child development, involvement in developmentally appropriate activities, and parental sense of competence.


Eligibility criteria:
inclusion criteria: * postpartum woman with baby in her care * receive well-woman care, well-child care and interviews in english * willingness to receive care in a group setting * woman planning to receive care at the yale women's center for herself and the primary care center for her baby exclusion criteria: * severe medical problem requiring individualized care for mother or baby * baby born at less than 37 weeks gestation * baby remaining in hospital when mother getting discharged for any other reason except hyperbilirubinemia * baby with severe cardiac, respiratory, neuro-developmental or surgical problems

Keywords: primary care, high-risk families, maternal depression
validation of withings sleep for the detection of sleep apnea syndrome

Conditions: Sleep Apnea Syndromes

Summary: sleep apnea syndrome (sas) is a common pathology affecting between 4 and 8% of the general population. it aggravates morbidity and cardio-metabolic mortality and is responsible for accidents related to vigilance disorders. it is estimated that 80% of sas cases are not diagnosed and therefore not treated. it is however impracticable to propose a diagnostic test of polygraphy (pg) or polysomnography (psg) to every patient because of the cost and insufficient availability of these exams. it would therefore be useful to carry out a screening test before directing the patient to a complete test. several simplified polygraph systems with 2 or 3 channels have been proposed (nasal cannula, oximetry, heart rate) but they generally record only one night and remain intrusive enough to perturb the sleep. the withings sleep is a non-contact device, along with an airbag placed under the mattress, which allows screening of sas from four signals: movement, breathing, heart rate and snoring. the objective of the present study is to validate the diagnostic performance of the withings sleep for the detection of sas compared to psg.


Eligibility criteria:
inclusion criteria: * adults, men or women, aged between 18 and 70 * patients referred for an overnight polysomnographic exam for a suspicion of sleep-disordered breathing exclusion criteria: * children less than 18 years of age * patients treated with continuous positive airway pressure * person not giving her consent * vulnerable subject according to current regulation: * pregnant woman, parturient or breastfeeding * subject deprived of freedom by judicial, medical or administrative decision * subject legally protected or unable to express his consent * subject non-beneficiary of healthcare * subject falling into more than one of the above categories * subject in linguistic or psychic incapacity to express his consent

Keywords: sleep apnea sleep apnea syndromes respiration disorders respiratory tract diseases signs and symptoms, respiratory signs and symptoms sleep apnea, obstructive sleep disorders, intrinsic dyssomnias sleep wake disorders nervous system diseases apnea
ofs in premenopausal node+ breast cancer with low genomic risk

Conditions: Breast Cancer; Estrogen Receptor Positive Tumor; HER2-negative Breast Cancer; Premenopausal Breast Cancer; Node-positive Breast Cancer

Summary: among er+her2- premenopausal patients with n1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (oncofree®). in these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.

* among er+her2- premenopausal patients with n1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (oncofree®). * in these, ovarian function suppression (ofs) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years. * either goserelin acetate or leuprorelin acetate is allowed. * these patients are able to choose bilateral salpingo-oophorectomy instead of ofs. * chemotherapy is omitted in these patients.

Eligibility criteria:
inclusion criteria: * er+her2- breast cancer * premenopausal and age \<=50 * t1 or t2 * n1 including micrometastasis * genomic low risk by oncofree test® (1-20) exclusion criteria: * postmenopausal women * er-negative breast cancer

Keywords: breast cancer estrogen receptor positive tumor her2-negative breast cancer premenopausal breast cancer node-positive breast cancer multigene assay ovarian-function suppression